NeuroSense ALS Trial Data Published, Paving Way for Phase 3
Event summary
- NeuroSense's PARADIGM Phase 2b trial of PrimeC in ALS patients was published in JAMA Neurology on March 16, 2026.
- The trial demonstrated a 7.92-point advantage in ALSFRS-R at 18 months (p=0.007) and a 64% relative reduction in ALS-related complications (p=0.02).
- PrimeC, a combination therapy of celecoxib and ciprofloxacin, showed modulation of ALS-related microRNAs and iron-regulatory biomarkers.
- The trial enrolled 68 participants across Italy, Canada, and Israel, with a 2:1 ratio of PrimeC to placebo during a 6-month blinded period followed by a 12-month open-label extension.
- Findings support advancement to a confirmatory Phase 3 clinical trial, which has already received FDA clearance.
The big picture
The publication of positive Phase 2b data for PrimeC represents a significant advancement in the ALS therapeutic landscape, a field with a high unmet need and limited treatment options. While the Phase 2b trial wasn't powered for definitive efficacy, the consistent clinical and biomarker findings provide a strong foundation for Phase 3 development. The success of PrimeC could represent a paradigm shift in ALS treatment, moving beyond symptomatic management towards disease modification, but faces the typical risks associated with late-stage clinical trials and commercialization.
What we're watching
- Phase 3 Execution
- The success of NeuroSense hinges on the efficient and effective execution of the Phase 3 trial, given the relatively modest sample size of the Phase 2b study.
- Biomarker Validation
- How consistently the observed biomarker modulation translates to clinical benefit in a larger Phase 3 cohort will be critical for establishing PrimeC’s disease-modifying potential.
- Competitive Landscape
- The emergence of other ALS therapies will likely intensify, potentially impacting PrimeC’s market share and pricing, requiring NeuroSense to demonstrate a clear clinical advantage.
Related topics